{{Rsnum
|rsid=2285714
|Gene=PLA2G12A
|Chromosome=4
|position=109717654
|Orientation=plus
|GMAF=0.27
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PLA2G12A
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 32.1 | 52.7 | 15.2
| HCB | 57.4 | 38.2 | 4.4
| JPT | 61.6 | 33.0 | 5.4
| YRI | 99.3 | 0.7 | 0.0
| ASW | 84.2 | 15.8 | 0.0
| CHB | 57.4 | 38.2 | 4.4
| CHD | 61.1 | 33.3 | 5.6
| GIH | 43.6 | 39.6 | 16.8
| LWK | 97.3 | 2.7 | 0.0
| MEX | 31.0 | 53.4 | 15.5
| MKK | 93.4 | 6.6 | 0.0
| TSI | 33.3 | 52.0 | 14.7
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=20385819
|Trait=Age-related macular degeneration
|Title=Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration
|RiskAllele=T
|Pval=3E-7
|OR=1.31
|ORtxt=[1.18-1.45]
|OA=1
}}

{{PMID Auto
|PMID=23112570
|Title=Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}